Research programme: infertility therapeutics - Merck Serono/Syntonix

Drug Profile

Research programme: infertility therapeutics - Merck Serono/Syntonix

Alternative Names: Follicle-stimulating hormone-Fc fusion protein; FSH-Fc; FSH:Fc SynFusion™ drugs; FSH:Fc SynFusion™ products

Latest Information Update: 25 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntonix Pharmaceuticals
  • Developer EMD Serono; Merck Serono; Syntonix Pharmaceuticals
  • Class Follicle stimulating hormones; Pituitary gonadotropins; Recombinant fusion proteins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Female infertility

Most Recent Events

  • 01 Feb 2007 Syntonix Pharmaceuticals has been acquired by Biogen Idec
  • 08 Jan 2007 Serono is now called Merck Serono
  • 05 Jan 2007 Serono has been acquired by Merck KGaA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top